都是外星来的谣棍吧?各地区的报告都有与疫苗相关的心肌炎病例统计。从来没有人否认过。
听懂福奇说的什么吗？心肌炎在 very very very low risk, Covid itself is greater risk then vaccine.
浏览附件1110289
这是安省报告:
MYOCARDITIS/PERICARDITIS
There have been international reports, including from the United States and Israel, of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) following vaccination with COVID-19 mRNA vaccines.11,12 Information to date indicates that these events occur more commonly after the second dose, within the week following vaccination (typically within 4-5 days), mainly in adolescents/young adults and more often in males than females.
PHAC and Health Canada are closely monitoring these events in passive and active Canadian vaccine safety surveillance systems.
As of August 28, 2021, there have been 331 reports of myocarditis or pericarditis following receipt of COVID-19 mRNA vaccines in Ontario. These reports have been identified through case-level review of all reported AEFIs. Of these, 87 (26.3%) were diagnosed with myocarditis and 139 (42.0%) were diagnosed with pericarditis. The remaining 105 (31.7%) were diagnosed with perimyocarditis (n=18), myopericarditis (n=84) and myocarditis/pericarditis (n=3). The 87 reports of myocarditis have been assessed using the Brighton Collaboration case definition for myocarditis; 80 reports met Brighton levels of diagnostic certainty 1, 2 or 3 (92.0%), two reports had insufficient evidence to meet level 1, 2 or 3 of the case definition (2.3%) and one report did not meet the Brighton Collaboration case definition for myocarditis (1.1%). 14 Four reports could not be assessed due to lack of information. Of the 139 reports of pericarditis assessed using the Brighton Collaboration case definition for pericarditis, 71 reports met Brighton levels of diagnostic certainty 1, 2 or 3 (51.1%), 49 reports had insufficient evidence to meet level 1, 2 or 3 of the case definition (35.3%), and 14 reports did not meet the Brighton Collaboration case definition for pericarditis (10.1%). 14 Five reports could not be assessed due to lack of information. See Table 3 for further characteristics of myocarditis/pericarditis reports. The remaining 105 reports were assessed against both Brighton Collaboration case definition for myocarditis and pericarditis to see if they meet either one of two definitions; of these, 89 (84.8%) met Brighton levels of diagnostic certainty 1, 2 or 3 for either myocarditis or pericarditis.
Of the 331 reports of myocarditis or pericarditis, 189 (57.1%) reports had a hospital admission with some variation by age group. Among the 163 reports where both the date of admission and discharge was available for review, the median length of stay was two days.
Based on 331 reports of myocarditis or pericarditis, the overall crude reporting rate is 16.9 per million doses of mRNA vaccines administered. The highest reporting rates were observed in younger age groups (12-17 and 18-24 years) and among males. The highest reporting rate was observed for males aged 18- 24 years of age following dose 2, at 164.0 events per million doses administered. Table A3 in Appendix A presents the reporting rate of myocarditis or pericarditis by age group, gender and dose number. The reporting rates are calculated by including all reports of myocarditis or pericarditis identified through case-level review, regardless of whether they meet the Brighton Collaboration case definition for myocarditis or pericarditis.
Additionally, there are 79 reports classified as ‘persons under investigation’ as public health units are still collecting additional information on the AEFI report. Ontario is continuing to monitor these events in collaboration with its partners and weekly updates can be found within this report and on the PHAC website. Please see PHO’s At A Glance: Myocarditis and Pericarditis Following COVID-19 mRNA Vaccines for more information on this topic.15Additional in-depth analysis of myocarditis/pericarditis reports in Ontario is available on Myocarditis and Pericarditis Following Vaccination with COVID-19 mRNA Vaccines in Ontario: December 13, 2020 to August 7, 2021. 16
Table 3. Characteristics of myocarditis or pericarditis reports received to date following COVID-19 mRNA vaccines: Ontario, December 13, 2020 to August 28, 2021
Note: Twenty-eight reports with unknown time to onset and four reports with time to onset of greater than 42 days have been excluded from the calculation of median time to onset and range.
www.canada.ca
